JP2002541776A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002541776A5 JP2002541776A5 JP2000601144A JP2000601144A JP2002541776A5 JP 2002541776 A5 JP2002541776 A5 JP 2002541776A5 JP 2000601144 A JP2000601144 A JP 2000601144A JP 2000601144 A JP2000601144 A JP 2000601144A JP 2002541776 A5 JP2002541776 A5 JP 2002541776A5
- Authority
- JP
- Japan
- Prior art keywords
- phex
- sec
- endopeptidase
- homology
- chromosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 13
- 229910019142 PO4 Inorganic materials 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 11
- 239000010452 phosphate Substances 0.000 description 11
- 102000005593 Endopeptidases Human genes 0.000 description 10
- 108010059378 Endopeptidases Proteins 0.000 description 10
- 108700005075 Regulator Genes Proteins 0.000 description 10
- 210000001766 X chromosome Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 239000003446 ligand Substances 0.000 description 5
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2,262,056 | 1999-02-24 | ||
| CA002262056A CA2262056A1 (en) | 1999-02-24 | 1999-02-24 | Composition, methods and reagents for the synthesis of a soluble form of human pex |
| PCT/CA2000/000201 WO2000050580A2 (en) | 1999-02-24 | 2000-02-24 | Composition, methods and reagents for the synthesis of a soluble form of human phex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002541776A JP2002541776A (ja) | 2002-12-10 |
| JP2002541776A5 true JP2002541776A5 (enExample) | 2007-03-15 |
Family
ID=4163297
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000601144A Pending JP2002541776A (ja) | 1999-02-24 | 2000-02-24 | ヒトｐｈｅｘの可溶性形態の組成物、方法及び合成試薬 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6790649B1 (enExample) |
| EP (1) | EP1159412A2 (enExample) |
| JP (1) | JP2002541776A (enExample) |
| AU (1) | AU776042B2 (enExample) |
| CA (1) | CA2262056A1 (enExample) |
| WO (1) | WO2000050580A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2418461A1 (en) | 2000-08-23 | 2002-02-28 | Biomep Inc. | Method and compositions for promoting osteogenesis |
| WO2002092128A1 (en) * | 2001-05-11 | 2002-11-21 | Genzyme Corporation | Compositions and methods to regulate serum phosphate |
| US7105539B2 (en) | 2002-12-03 | 2006-09-12 | Enobia Pharma | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex |
| WO2004085465A1 (en) * | 2003-03-26 | 2004-10-07 | Enobia Pharma Inc. | Phex substrates and methods using same |
| HUE055861T2 (hu) | 2004-04-21 | 2021-12-28 | Alexion Pharma Inc | Csontbejuttató konjugátumok és azok alkalmazási módszere fehérjék csonthoz kötéséhez |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| AU2011245005A1 (en) | 2010-04-30 | 2012-11-22 | Alexion Pharma Holding | Methods, compositions, and kits for the treatment of matrix mineralization disorders |
| CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| CA2967851C (en) | 2014-12-05 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| RU2745528C2 (ru) | 2015-08-17 | 2021-03-26 | Алексион Фармасьютикалз, Инк. | Производство щелочных фосфатаз |
| WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| EP3436020A4 (en) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | METHOD FOR TREATING HYPOPHOSPHATASIE IN TEENS AND ADULTS |
| JP7613826B2 (ja) | 2016-04-01 | 2025-01-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| CA3057502A1 (en) | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
| JP2021519590A (ja) | 2018-03-30 | 2021-08-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 糖タンパク質の製造 |
| JP2021534111A (ja) | 2018-08-10 | 2021-12-09 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法 |
| US12433938B2 (en) | 2019-12-09 | 2025-10-07 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| CN115335696B (zh) * | 2020-03-27 | 2024-04-30 | 积水医疗株式会社 | 液相色谱用构件 |
| AU2022218782A1 (en) | 2021-02-12 | 2023-08-17 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5840509A (en) * | 1996-07-22 | 1998-11-24 | Eli Lilly And Company | Protease and related nucleic acid compounds |
| CA2264955A1 (en) | 1996-09-05 | 1998-03-12 | Andrew C. Karaplis | Cloning of full-length human pex cdna |
-
1999
- 1999-02-24 CA CA002262056A patent/CA2262056A1/en not_active Abandoned
-
2000
- 2000-02-24 US US09/913,955 patent/US6790649B1/en not_active Expired - Lifetime
- 2000-02-24 AU AU27900/00A patent/AU776042B2/en not_active Ceased
- 2000-02-24 WO PCT/CA2000/000201 patent/WO2000050580A2/en not_active Ceased
- 2000-02-24 JP JP2000601144A patent/JP2002541776A/ja active Pending
- 2000-02-24 EP EP00906114A patent/EP1159412A2/en not_active Withdrawn
-
2004
- 2004-06-08 US US10/862,459 patent/US7427498B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002541776A5 (enExample) | ||
| US10352930B2 (en) | Multiplex immuno screening assay | |
| WO2000050580B1 (en) | Composition, methods and reagents for the synthesis of a soluble form of human phex | |
| US6417331B1 (en) | Recombinant inactive core streptavidin mutants | |
| AU697227B2 (en) | Enzyme for cleavage of the anchor region of surface proteins from gram positive bacteria | |
| JP2968048B2 (ja) | 表面プラズモン共鳴に基づく酵素アッセイ | |
| JP2003501038A5 (enExample) | ||
| US20130196336A1 (en) | Transglutaminase 6 as a diagnostic indicator of autoimmune diseases | |
| WO2020198264A1 (en) | Modified cleavases, uses thereof and related kits | |
| Hansbauer et al. | Detection, differentiation, and identification of botulinum neurotoxin serotypes C, CD, D, and DC by highly specific immunoassays and mass spectrometry | |
| Jacotot et al. | Dipeptidyl‐Peptidase IV‐β, a Novel form of Cell‐Surface‐Expressed Protein with Dipeptidyl‐Peptidase IV Activity | |
| JP2001521744A5 (enExample) | ||
| CA2186573A1 (en) | Sh2-containing inositol-phosphatase | |
| CN114127281A (zh) | 邻近相互作用分析 | |
| JP2003531634A5 (enExample) | ||
| US6391571B1 (en) | Recombinant inactive avidin mutants | |
| JP5305259B2 (ja) | 抗シトルリン化ｇｆａｐモノクローナル抗体及びその用途 | |
| JP2009240235A (ja) | 融合タンパク質、遺伝子、融合タンパク質の製造方法、並びに、抗原タンパク質の検出方法 | |
| JP6020886B2 (ja) | 抗体認識結合タンパク質 | |
| Rival et al. | On the mechanism of action of pseudolysin: kinetic study of the enzymatic condensation of Z-Ala with Phe-NH2 | |
| CA2597545A1 (en) | Antibody for assay of adamts13 activity and method for assaying the activity | |
| JP4406298B2 (ja) | アミノペプチダーゼ | |
| CN104849462B (zh) | 一种高灵敏度抗cd20单克隆抗体及其应用 | |
| CN100497619C (zh) | 鞘脂神经酰胺脱酰基酶基因 | |
| WO2006097564A3 (es) | Nueva proteina epcr soluble de origen no proteolitico y su uso |